PRN 08/12 12:50 Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection)
BN 08/12 12:50 *SANOFI LAUNCHES AUTHORIZED GENERIC VERSION OF ELOXATIN®
BN 08/12 12:50 *SANOFI LAUNCHES AUTHORIZED GENERIC VERSION OF ELOXATIN®
Sanofi Introduces Generic Version of Eloxatin
2014-08-12 12:55:31.626 GMT
By Allison Connolly
Aug. 12 (Bloomberg) -- Co. says its generics division
Winthrop U.S. has introduced a generic version of Eloxatin
(oxaliplatin injection).
* Sanofi holds original patent; generic is same formulation
* Used in treatment of advanced colorectal cancer or as
adjuvant treatment of stage III colon cancer in patients who
have undergone complete resection of the primary tumor
* NOTE: Branded drug lost market exclusivity in U.S. in Aug.
2012
Link to Statement:{NSN NA72C73MMTC0 <GO>}
Link to Company News:{SAN FP <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
Allison Connolly at +44-20-3525-7043 or
aconnolly4@bloomberg.net
2014-08-12 12:55:31.626 GMT
By Allison Connolly
Aug. 12 (Bloomberg) -- Co. says its generics division
Winthrop U.S. has introduced a generic version of Eloxatin
(oxaliplatin injection).
* Sanofi holds original patent; generic is same formulation
* Used in treatment of advanced colorectal cancer or as
adjuvant treatment of stage III colon cancer in patients who
have undergone complete resection of the primary tumor
* NOTE: Branded drug lost market exclusivity in U.S. in Aug.
2012
Link to Statement:{NSN NA72C73MMTC0 <GO>}
Link to Company News:{SAN FP <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
Allison Connolly at +44-20-3525-7043 or
aconnolly4@bloomberg.net